Abstract
Candida auris is an emergent multidrug-resistant pathogenic yeast with an unprecedented ability for a fungal organism to easily spread between patients in clinical settings, leading to major outbreaks in healthcare facilities. The formation of biofilms by C. auris contributes to infection and its environmental persistence. Most antifungals and sanitizing procedures are not effective against C. auris, but antimicrobial nanomaterials could represent a viable alternative to combat the infections caused by this emerging pathogen. We have previously described an easy and inexpensive method to synthesize silver nanoparticles (AgNPs) in non-specialized laboratories. Here, we have assessed the antimicrobial activity of the resulting AgNPs on C. auris planktonic and biofilm growth phases. AgNPs displayed a strong antimicrobial activity against all the stages of all C. auris strains tested, representative of four different clades. Under planktonic conditions, minimal inhibitory concentration (MIC) values of AgNPs against the different strains were <0.5 μg ml−1; whereas calculated IC50 values for inhibition of biofilms formation were <2 μg ml−1 for all, but one of the C. auris strains tested. AgNPs were also active against preformed biofilms formed by all different C. auris strains, with IC50 values ranging from 1.2 to 6.2 μg ml−1. Overall, our results indicate potent activity of AgNPs against strains of C. auris, both under planktonic and biofilm growing conditions, and indicate that AgNPs may contribute to the control of infections caused by this emerging nosocomial threat.
Highlights
Candida auris is an emergent multidrug-resistant yeast that has been reported worldwide since its detection in Japan in 2009 (Centers for Disease Control and Prevention, 2019)
Our results show that AgNPs display potent antifungal activity at very low concentrations in virtually all C. auris strains tested
AgNPs minimal fungicidal concentration (MFC) was higher in strain antimicrobial resistance (AR) #0381 (32 μg ml−1)
Summary
Candida auris is an emergent multidrug-resistant yeast that has been reported worldwide since its detection in Japan in 2009 (Centers for Disease Control and Prevention, 2019). C. auris spreads in healthcare settings, posing a risk for hospital patients due to its high mortality rate invasive infections and its healthcare-associated outbreaks (Sears and Schwartz, 2017; Forsberg et al, 2019). It contaminates surfaces and medical instrumentation within healthcare facilities for long periods, which poses a risk factor in healthcare facilities worldwide (Sears and Schwartz, 2017). C. auris is considered as an urgent threat by the Centers for Disease Control and Prevention (CDC), according to their “Antibiotic Resistance Threats in the United States, 2019” (CDC, 2019a)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have